At a glance
Summary
IQVIA Holdings closed at 238.7 USD for the week ended 7 August, up 1.6% and only 5.0% below its 52-week high of 251.4 USD. The stock has advanced 14.8% over four weeks and 41.1% over 12 weeks, leaving it 27.1% above the weekly Trend Line and 17.4% above Sharemaestro Fair Value. The read is constructive but not clean: the Trend Signal is active, activity pressure is positive, Relative Strength is positive, yet volume was below baseline and the setup carries negative next-week expectancy at 43.72%.
- IQVIA closed at 238.7 USD, up 1.6% on the week and positioned at 86.9% of its 52-week range.
- The 12-week return of 41.1% is the main strength signal, well ahead of the US Healthcare average of 12.7% and the US Diagnostics & Research average of 33.1%.
- Price is 27.1% above the weekly Trend Line at 187.8 USD and 17.4% above Sharemaestro Fair Value at 203.3 USD, showing strong demand but also a wider valuation gap.
- Latest volume was 7.0M shares, or 0.9x the 13-week average of 7.6M and 0.9x the 52-week average of 7.9M, so participation did not fully confirm the move.
- The signal state is mixed: Trend backdrop active, activity pressure positive at 1.16, Relative Strength positive at 7.86, but activity pressure shows no fresh buy and next-week expectancy is negative.
Company analysis
The move in context
Price action: strong quarter, narrower weekly edge
IQVIA’s 1.6% weekly gain kept the clinical research and health information services group near the top of its yearly range. At 238.7 USD, the stock is 86.9% of the way from its 52-week low of 154.5 USD to its 52-week high of 251.4 USD, leaving a 5.0% high-water gap. The short-term move is more powerful than the latest week suggests: IQV has gained 14.8% over four weeks and 41.1% over 12 weeks, while the 26-week and 52-week returns stand at 27.3% and 32.7% respectively.
The Trend backdrop is active, although the current active streak is only one week. Price is 27.1% above the weekly Trend Line at 187.8 USD, which keeps the broader weekly regime constructive. It is also 17.4% above Sharemaestro Fair Value at 203.3 USD, a sign of premium demand, but one that raises the burden for continued follow-through if momentum cools.
Healthcare context: IQV trails the week but beats the month and quarter
The sector read is mixed. US Healthcare averaged a 2.5% weekly return, ahead of IQVIA’s 1.6%, but the stock’s 14.8% four-week return ranks much better against the sector’s 2.6% average. Over 12 weeks, IQVIA’s 41.1% gain is far above the sector average of 12.7%, placing it fifth within the supplied Healthcare sector set for the period.
Within US Diagnostics & Research, the latest week was even stronger at the group level, with an average gain of 5.9%, so IQVIA underperformed its industry peers in the most recent week. The longer window is more supportive: the industry averaged 6.0% over four weeks and 33.1% over 12 weeks, both below IQVIA’s returns. Breadth is constructive but not broad-based in relative terms, with 55.6% of industry names showing active Trend Signals and 80.0% showing positive activity pressure, while only 42.2% show positive Relative Strength.
Market Dynamics and volume: positive pressure, modest participation
Market Dynamics are supportive but not decisive. Activity pressure is positive at 1.16 and has improved over the recent four-week window, while Relative Strength is also positive at 7.86 after a sharp recovery from negative readings in July. That improvement supports the 12-week advance, but the signal panel still shows no fresh activity-pressure buy, so the latest state is better described as constructive rather than emphatic.
Volume is the main caveat. The latest week traded 7.0M shares, below the 13-week average of 7.6M and the 52-week average of 7.9M. That contrasts with the 31 July week, when IQVIA rose 13.0% on 12.5M shares, and with earlier high-volume advances such as 8 May and 26 June. For a stock already sitting 17.4% above Fair Value, a stronger volume ratio would make the next move more credible.
Risk and watch next
Risk is not excessive by recent standards, but it is not absent. The 13-week weekly-return volatility is 6.3%, slightly above the 52-week base of 6.1%. The 52-week split still leans negative by count, with 23 upside weeks and 28 downside weeks, although the average gain of 5.8% is larger than the average loss of 3.4%. The risk panel also flags negative next-week expectancy at 43.72% and two recent reversal markers in the smart-money read.
The immediate test is whether IQVIA can hold its high-range position without relying on thin participation. The weekly Trend Line remains the key regime level, activity pressure is the gauge for confirmation or fade, and a volume ratio above 1.5x would show that institutions are more heavily involved in the next move. A push back toward the 251.4 USD high with stronger volume would improve the quality of the advance; a failure while stretched above Fair Value would make the 203.3 USD fair-value area more relevant as a reference point.
Peer comparison
How the wider group is behaving
Breadth shows how much of the sector or industry is participating. A company move is more convincing when its peers are improving too.
US Healthcare
100 tracked companiesAbove Trend Line54.0%
Positive Relative Strength44.0%
US Diagnostics & Research
45 tracked companiesAbove Trend Line55.6%
Positive Relative Strength42.2%
Balanced view
What supports the case, and what could weaken it
What is working
- The trend backdrop is active with a 1-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
What needs caution
- Next-week expectancy is negative at 43.72% based on similar historical setup states.
- 2 reversal markers appear in the recent smart-money tape.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/iqvia-41-percent-quarter-volume-confirmation/.
Follow new Sharemaestro research through the RSS feed or JSON feed.